Skip to content
Inciteful Med

The Biology of GA1: Understanding the 'Low-Excretor' Challenge

Last updated:

Glutaric Aciduria Type 1 (GA1) is caused by a GCDH gene mutation that prevents the breakdown of lysine and tryptophan. Children with the "low-excretor" type spill less acid in their urine, putting them at high risk for false-negative newborn screens despite facing the same risk of brain injury.

Key Takeaways

  • • GA1 is caused by a mutation in the GCDH gene that prevents the body from breaking down the amino acids lysine and tryptophan.
  • • The toxic build-up of glutaric acid and 3-OH-GA can cause severe neurological damage to a part of the brain called the striatum.
  • • Children who are 'low excretors' have lower toxin levels in their urine but face the exact same risk of brain injury as high excretors.
  • • Because their toxin levels appear almost normal, low excretors are at a dangerously high risk for false-negative newborn screening results.
  • • Macrocephaly (a larger than average head size) is an early physical clue of GA1 that should prompt further testing even if the newborn screen was normal.

Glutaric Aciduria Type 1 (GA1) is a rare genetic condition that affects how the body breaks down certain proteins [1]. While the name and the science behind it can feel overwhelming, understanding the biology of the condition is the first step in protecting your child’s health.

The GCDH Gene and the “Broken” Enzyme

Every person has a gene called GCDH [1]. This gene provides instructions for making an enzyme (a specialized protein) called glutaryl-CoA dehydrogenase [1][2].

Think of this enzyme like a key worker in a recycling plant. Its job is to help break down two specific amino acids (the building blocks of protein) found in the food we eat: lysine and tryptophan [3]. In children with GA1, the GCDH gene has a “typo” (mutation), which means the enzyme doesn’t work correctly or is missing entirely [4].

The Toxic Build-up

Because the enzyme isn’t working, the body cannot finish breaking down lysine and tryptophan [3]. Instead, the process gets stuck, and “trash” starts to pile up in the body. The two main toxic substances that build up are:

  • Glutaric Acid (GA) [1]
  • 3-hydroxyglutaric acid (3-OH-GA) [5]

In high amounts, these substances are neurotoxic, meaning they can be harmful to the brain, specifically a part of the brain called the striatum, which controls movement [6][5].

The ‘Low-Excretor’ Trap: A Critical Warning

One of the most confusing parts of GA1 is that it presents in two different biochemical “types.” It is vital to understand that these types describe how much “trash” shows up in the urine, not how sick the child is.

  • High Excretors (HE): These children have very little enzyme activity and “spill” large amounts of GA into their urine. They are usually easy to detect on newborn screenings [7][8].
  • Low Excretors (LE): These children may have a tiny bit more enzyme activity, but they “spill” very little GA into their urine—sometimes the levels look almost normal [9][10].

The Trap: Because low excretors have lower levels of toxins in their blood and urine, they are at a high risk for false-negative newborn screenings [11][12]. Their initial test might come back as “normal” even though they have GA1 [9].

Important: Being a “low excretor” does not mean your child has a “mild” case. Low excretors face the exact same risk of sudden brain injury (metabolic crisis) as high excretors [13][10].

Macrocephaly: An Early Clue

Many children with GA1 are born with or develop macrocephaly (a head size that is larger than average) [14][15]. This happens because the brain may have extra fluid or unique “gaps” (widened Sylvian fissures) that make the head appear larger [16][17]. If a baby has a large head and a “borderline” or “normal” newborn screen, doctors should still consider GA1 as a possibility [18][19].

Confirming the Diagnosis

Because of the “low-excretor trap,” doctors use several tests to be certain:

  1. Acylcarnitine Profile (C5DC): This blood test looks for glutarylcarnitine, the primary marker used in newborn screening [20].
  2. Urine Organic Acids: This test measures GA and 3-OH-GA levels. For low excretors, the 3-OH-GA level is often the more reliable marker [10][9].
  3. Genetic Testing: This is the “gold standard.” By looking directly at the GCDH gene, doctors can confirm the diagnosis regardless of what the urine or blood tests show [11][6]. Specific mutations, such as R227P, are often linked to the low-excretor type [21][22].

Frequently Asked Questions

What is the difference between a high excretor and a low excretor in GA1?
High excretors release large amounts of glutaric acid into their urine, while low excretors release very little. However, both types face the exact same risk for severe metabolic crises and brain injury.
Can a child with GA1 have a normal newborn screening test?
Yes. Children who are "low excretors" have very low levels of toxins in their blood and urine at birth. This puts them at a high risk for a false-negative newborn screening result, meaning the test looks normal even though they have the condition.
Why do babies with GA1 often have larger heads?
Many children with GA1 develop macrocephaly, which means their head size is larger than average. This happens because of extra fluid in the brain or unique gaps called widened Sylvian fissures.
How is a GA1 diagnosis confirmed if the newborn screen is normal?
If a newborn screen is normal but GA1 is suspected due to symptoms like a large head size, doctors use genetic testing to look for mutations in the GCDH gene. They may also run a urine organic acids test to check 3-OH-GA levels, which is a more reliable marker for low excretors.

Questions for Your Doctor

  • • Is my child considered a 'high excretor' or a 'low excretor' based on their urine tests?
  • • If my child is a low excretor, how does this affect our ongoing monitoring and testing plan?
  • • What were my child's specific glutarylcarnitine (C5DC) levels on their newborn screen?
  • • Can you explain the specific GCDH gene mutations found in my child and what they mean for their enzyme function?
  • • How often should we monitor my child's head circumference, and what measurement would be considered a 'warning sign'?
  • • Are there specific findings on my child's brain MRI, like widened Sylvian fissures, that we should be aware of?

Questions for You

  • • When did I first notice my child's head size seemed larger than other babies? Was it present at birth?
  • • Did my child pass their newborn screening, or was the diagnosis found later because of symptoms?
  • • How has my child's development (sitting, crawling, head control) progressed so far?
  • • What are the most stressful parts of this diagnosis for me right now, and what kind of support do I need?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Elevated glutaric acid levels in Dhtkd1-/Gcdh- double knockout mice challenge our current understanding of lysine metabolism.

    Biagosch C, Ediga RD, Hensler SV, et al.

    Biochimica et biophysica acta. Molecular basis of disease 2017; (1863(9)):2220-2228 doi:10.1016/j.bbadis.2017.05.018.

    PMID: 28545977
  2. 2

    Recommendations for diagnosing and managing individuals with glutaric aciduria type 1: Third revision.

    Boy N, Mühlhausen C, Maier EM, et al.

    Journal of inherited metabolic disease 2023; (46(3)):482-519 doi:10.1002/jimd.12566.

    PMID: 36221165
  3. 3

    Deglutarylation of glutaryl-CoA dehydrogenase by deacylating enzyme SIRT5 promotes lysine oxidation in mice.

    Bhatt DP, Mills CA, Anderson KA, et al.

    The Journal of biological chemistry 2022; (298(4)):101723 doi:10.1016/j.jbc.2022.101723.

    PMID: 35157847
  4. 4

    Glutaryl-CoA Dehydrogenase Misfolding in Glutaric Acidemia Type 1.

    Barroso M, Gertzen M, Puchwein-Schwepcke AF, et al.

    International journal of molecular sciences 2023; (24(17)) doi:10.3390/ijms241713158.

    PMID: 37685964
  5. 5

    Impairment of astrocytic glutaminolysis in glutaric aciduria type I.

    Komatsuzaki S, Ediga RD, Okun JG, et al.

    Journal of inherited metabolic disease 2018; (41(1)):91-99 doi:10.1007/s10545-017-0096-5.

    PMID: 29098534
  6. 6

    [Complex heterogeneity phenotypes and genotypes of glutaric aciduria type 1].

    Wang Q, Yang YL

    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 2016; (18(5)):460-5.

    PMID: 27165598
  7. 7

    Phenotypic prediction in glutaric aciduria type 1 combining in silico and in vitro modeling with real-world data.

    Yuan Y, Dimitrov B, Boy N, et al.

    Journal of inherited metabolic disease 2023; (46(3)):391-405 doi:10.1002/jimd.12618.

    PMID: 37078465
  8. 8

    Biochemical, molecular, and clinical features of patients with glutaric acidemia type 1 identified through large-scale newborn screening in Zhejiang Province, China.

    Lin Y, Zhu X, Zhang C, et al.

    Clinica chimica acta; international journal of clinical chemistry 2022; (530()):113-118 doi:10.1016/j.cca.2022.03.026.

    PMID: 35367405
  9. 9

    Is Expanded Newborn Screening Adequate to Detect Indian Biochemical Low Excretor Phenotype Patients of Glutaric Aciduria Type I?

    Shaik M, T P KV, Kamate M, A B V

    Indian journal of pediatrics 2019; (86(11)):995-1001 doi:10.1007/s12098-019-03017-z.

    PMID: 31302874
  10. 10

    Enhanced differentiation between 3-hydroxyglutaric and 2-hydroxyglutaric acids facilitates diagnostic testing for glutaric aciduria type 1.

    Cyr D, Boutin M, Maranda B, Waters PJ

    JIMD reports 2024; (65(6)):433-441 doi:10.1002/jmd2.12447.

    PMID: 39512438
  11. 11

    Low excretor glutaric acidemia type 1 with transient lesions in the basal ganglia.

    Miyata Y, Murayama K, Okazaki Y, et al.

    Brain & development 2025; (47(4)):104380 doi:10.1016/j.braindev.2025.104380.

    PMID: 40517577
  12. 12

    The low excretor phenotype of glutaric acidemia type I is a source of false negative newborn screening results and challenging diagnoses.

    Guenzel AJ, Hall PL, Scott AI, et al.

    JIMD reports 2021; (60(1)):67-74 doi:10.1002/jmd2.12217.

    PMID: 34258142
  13. 13

    Glutaric Acidemia Type 1: Diagnosis, Clinical features, and Outcome in a Portuguese Cohort.

    Pinto PL, Câmara B, Florindo C, et al.

    Endocrine, metabolic & immune disorders drug targets 2023; doi:10.2174/1871530323666230914122946.

    PMID: 37711119
  14. 14

    Getting the diagnostic clue, role of MRI in the diagnosis of type 1 Glutaric aciduria in resource-limited settings.

    Regmi PR, Yadav AK, Koirala B, et al.

    Radiology case reports 2024; (19(9)):3701-3704 doi:10.1016/j.radcr.2024.05.040.

    PMID: 38983300
  15. 15

    Characterization of novel GCDH pathogenic variants causing glutaric aciduria type 1 in the southeast of Mexico.

    Campos-Garcia FJ, Chacon-Camacho OF, Contreras-Capetillo S, et al.

    Molecular genetics and metabolism reports 2019; (21()):100533 doi:10.1016/j.ymgmr.2019.100533.

    PMID: 31788423
  16. 16

    Enlargement of the Optic Chiasm: A Novel Imaging Finding in Glutaric Aciduria Type 1.

    Ntorkou AA, Daire J, Renaldo F, et al.

    AJNR. American journal of neuroradiology 2021; (42(9)):1722-1726 doi:10.3174/ajnr.A7199.

    PMID: 34244130
  17. 17

    Glutaric aciduria type 1: neuroimaging features with clinical correlation.

    Mohammad SA, Abdelkhalek HS, Ahmed KA, Zaki OK

    Pediatric radiology 2015; (45(11)):1696-705 doi:10.1007/s00247-015-3395-8.

    PMID: 26111870
  18. 18

    Subdural Hematoma in an Infant with Glutaric Aciduria Type 1: A Case Report on Conservative Management.

    Marques L, Lipari Pinto P, Loureiro Cadilha H, et al.

    Acta medica portuguesa 2025; (38(8)):496-501 doi:10.20344/amp.23093.

    PMID: 40775234
  19. 19

    Reversible brain atrophy in glutaric aciduria type 1.

    Numata-Uematsu Y, Sakamoto O, Kakisaka Y, et al.

    Brain & development 2017; (39(6)):532-535 doi:10.1016/j.braindev.2017.01.003.

    PMID: 28143689
  20. 20

    Evaluation of the first 5 years of a glutaric aciduria type I neonatal screening programme in Asturias.

    Elola Pastor AI, Prieto García B, Díaz Martín JJ

    Anales de pediatria 2024; (100(5)):318-324 doi:10.1016/j.anpede.2024.04.011.

    PMID: 38714461
  21. 21

    The M405V allele of the glutaryl-CoA dehydrogenase gene is an important marker for glutaric aciduria type I (GA-I) low excretors.

    Schillaci LA, Greene CL, Strovel E, et al.

    Molecular genetics and metabolism 2016; (119(1-2)):50-6.

    PMID: 27397597
  22. 22

    Potential complementation effects of two disease-associated mutations in tetrameric glutaryl-CoA dehydrogenase is due to inter subunit stability-activity counterbalance.

    Ribeiro JV, Lucas TG, Bross P, et al.

    Biochimica et biophysica acta. Proteins and proteomics 2020; (1868(1)):140269 doi:10.1016/j.bbapap.2019.140269.

    PMID: 31491587

This page explains the biology and screening challenges of GA1 for educational purposes only. Always consult a pediatric metabolic specialist or geneticist for your child's specific diagnosis and medical care.

Stay up to date

Get notified when new research about Glutaryl-CoA dehydrogenase deficiency is published.

No spam. Unsubscribe anytime.